Systems that use ultrasound to enhance medical treatment
Through ultrasound-enhanced medical treatment system, ultrasound imaging guides and robotic arms to deliver treatment ultrasound energy and drugs, monitor and adjust the treatment location in real time, solving the problem of poor absorption of drugs in cancer lesions, and achieving efficient and non-invasive drug delivery and therapeutic effects.
Patent Information
- Application Number
- CN201910676496.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-13
- Filing Date
- 2019-07-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-07-25
AI Technical Summary
In the prior art, when drug delivery to cancer lesions using drugs, the drug absorption effect is poor, making it difficult to effectively improve the drug delivery effect.
Using ultrasonic enhanced medical treatment system, combining ultrasonic imaging guidance, robotic arm and energy feedback control, the transducer module delivers therapeutic ultrasonic energy and drugs at the end of the robotic arm, monitors the target position and cavitation status in real time, and adjusts the treatment position and drug dosage. To enhance drug absorption.
It improves the absorption effect of drugs at cancer lesions, achieves non-invasive and efficient drug delivery, reduces the complexity and cost of treatment, and enhances the targetedness and effectiveness of treatment.
Smart Images

Figure CN111920446B_ABST
Abstract
Description
[0001] This application claims priority to U.S. patent application No. 62 / 847,253, filed with the U.S. Patent Office on May 13, 2019, and entitled “SYSTEMS AND METHODS FOR ENHANCED MEDICAL TREATMENT USING ULTRASOUND”, the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present invention relates to a non-invasive system for applying ultrasonic energy for treatment through real-time ultrasonic imaging guidance based on cavitation monitoring, a robotic arm and an energy feedback control loop, and more particularly to a system for using ultrasound to enhance medical treatment. Background Art
[0003] Many international scientific research results show that the combined use of cancer immunotherapy, chemotherapy and focused ultrasound therapy can greatly improve the quality of life of cancer patients and reduce the cost of care, reduce the systemic toxicity caused by chemotherapy, improve the effective uptake of drugs, and prolong life. However, the current technology and devices used for drug delivery only deliver drugs to the target lesion tissue, and the drugs cannot be well absorbed by the lesion.
[0004] Therefore, how to enhance the effect of drug delivery to the lesion is a technical problem that needs to be solved urgently by those skilled in the art. Summary of the invention
[0005] In view of the above, an object of the present invention is to provide a system for enhancing medical treatment using ultrasound to enhance the effect of drugs delivered to lesions.
[0006] The present invention provides a system for enhancing medical treatment using ultrasound, comprising:
[0007] An ultrasound imaging display capable of displaying an anatomical ultrasound image of a target;
[0008] a treatment monitoring display capable of displaying in real time the anatomical ultrasound imaging of the target, the cavitation state of the target, and the position information of the target;
[0009] A robotic arm capable of moving freely in space;
[0010] a transducer module, the transducer module being configured at the end of the robotic arm to move along the target, wherein the transducer module is capable of delivering therapeutic ultrasound energy to the location of the target, detecting the location of the target, obtaining ultrasound imaging information of the target, and monitoring the cavitation state of each of the targets;
[0011] a drug delivery unit capable of delivering a therapeutic agent and / or an ultrasound contrast agent to the target, wherein the drug delivery unit is delivered synchronously with the therapeutic ultrasound energy from the transducer module; and
[0012] An ultrasonic engine control system comprises a computing unit real-time controller, wherein the computing unit real-time controller controls the movement of the robotic arm, controls the delivery of therapeutic ultrasonic energy from the transducer module, and processes the cavitation state received by the anatomical ultrasonic imaging from the transducer module and the spatial position of the transducer module, and is used for real-time display of anatomical ultrasonic imaging of the target, target position tracking motion compensation, cavitation monitoring, ultrasonic energy output control, and delivery of drug doses and delivery control of the drug delivery unit.
[0013] In a specific embodiment, the transducer module includes separate transducer elements for each function, including a therapeutic transducer, an imaging transducer, and one or more broadband receive sensors.
[0014] In another specific embodiment, the transducer module includes a single multifunctional transducer array integrated with the functionality of transmitting therapeutic ultrasound energy, detecting target location, and monitoring cavitation conditions from corresponding transducer elements.
[0015] In another specific embodiment, the transducer module further comprises a frame surrounding the transducer element.
[0016] In another specific embodiment, the transducer module is detachably mounted on the robot arm.
[0017] In another specific embodiment, the robotic arm has six degrees of freedom of movement.
[0018] In another specific embodiment, the transducer module sends a signal to the ultrasonic engine control system via a cable line or wirelessly.
[0019] In another specific embodiment, the number of the robotic arms is two, one of the robotic arms is mounted with the therapeutic transducer, and the other robotic arm is mounted with the imaging sensor and one or more of the broadband receiving transducers.
[0020] In another specific embodiment, the number of the robotic arms is three, one of the robotic arms is mounted with the therapeutic transducer, one of the robotic arms is mounted with the imaging transducer, and another of the robotic arms is mounted with one or more broadband receiving transducers.
[0021] In another specific embodiment, the system further comprises an interface, through which the movement of the robotic arm is controlled to achieve remote control of the system, and the interface is capable of providing image data to a remotely controlled location.
[0022] In another specific embodiment, the anatomical ultrasound imaging is from a B-mode image or a 3D reconstructed image of multiple ultrasound images.
[0023] In another specific embodiment, the imaging from the treatment monitoring display is a ID map showing the cavitation state over time, and / or a 2D map of the cavitation state overlaid on the anatomical ultrasound imaging.
[0024] In another specific embodiment, the therapeutic transducer is capable of generating pulses for inducing steady-state or inertial cavitation with or without the ultrasound contrast agent.
[0025] In another specific embodiment, said imaging transducer receives pulses for ultrasonic imaging of said anatomy.
[0026] In another specific embodiment, the broadband receiving sensor receives pulses for cavitation monitoring or cavitation imaging.
[0027] In another specific embodiment, the ultrasonic engine control system also includes a robotic arm spatial position control subsystem under the control of a dose plan calculation delivery timing control module to control the spatial movement of the robotic arm, and the dose plan calculation delivery timing control module is included in the computing unit real-time controller.
[0028] In another specific embodiment, the ultrasonic engine control system also includes an ultrasonic imaging target tracking subsystem, wherein the ultrasonic imaging target tracking subsystem receives the anatomical ultrasonic imaging from the transducer module at each target position and transmits it to the computing unit real-time controller.
[0029] In another specific embodiment, the computing unit real-time controller includes a 3D image registration and reconstruction module and the dose plan calculation and delivery timing control module.
[0030] In another specific embodiment, the 3D image registration reconstruction module reconstructs a 3D volumetric image of the target using ultrasound imaging of each target location and the corresponding spatial location of the transducer module.
[0031] In another specific embodiment, the dose plan calculation delivery timing control module processes the target position and 3D volume image of the target, and sends a motion compensation signal to the robotic arm spatial position control subsystem to perform motion compensation at each of the target positions.
[0032] In another specific embodiment, the ultrasonic engine control system also includes a cavitation therapy monitoring subsystem to provide real-time monitoring of the cavitation state, and as an input for the dose plan calculation delivery time sequence, the control module generates a dose compensation plan and a delivery time sequence, wherein the cavitation therapy monitoring subsystem receives a cavitation state signal from the transducer module at each of the target positions.
[0033] In another specific embodiment, the dose compensation plan delivery time series is generated by overlaying the cavitation state input of each target location onto an ultrasound image of each of the target locations.
[0034] In another specific embodiment, the ultrasonic engine control system further comprises an ultrasonic therapy subsystem, wherein the ultrasonic therapy subsystem controls the transducer module to deliver therapeutic ultrasonic energy.
[0035] In another specific embodiment, the ultrasonic engine control system includes a drug delivery control subsystem, wherein the drug delivery control subsystem controls the drug delivery unit to deliver the therapeutic agent and / or the ultrasonic contrast agent.
[0036] In another specific embodiment, the dose compensation plan and delivery time sequence generated from the dose plan calculation delivery timing control module instructs the ultrasound treatment subsystem to adjust the dose and delivery time of the therapeutic ultrasound, and instructs the drug delivery control subsystem to adjust the dose and delivery time of the therapeutic agent and / or the ultrasound contrast agent.
[0037] The various embodiments according to the present invention can be arbitrarily combined as needed, and the embodiments obtained after these combinations are also within the scope of the present invention and are part of the specific implementation methods of the present invention.
[0038] The present invention provides a superior and easy-to-use non-invasive system for enhancing drug delivery to lesions using ultrasound. When in use, the real-time controller of the computing unit of the ultrasonic engine control system controls the mechanical arm to drive the transducer module to move to the target position, and the drug delivery unit delivers the drug to the target and the transducer module delivers the therapeutic ultrasonic energy to the target synchronously. The transducer module can transmit the acquired target ultrasonic imaging information and the monitored cavitation state of each target to the ultrasonic engine control system, and the ultrasonic engine control system can adjust the treatment position at any time according to this information. The present invention controls the transducer module to deliver the therapeutic ultrasonic energy to the target through the ultrasonic engine control system, and synchronously controls the drug delivery unit to deliver the required amount of drug to the target, and the therapeutic ultrasonic energy enhances the absorption effect of the drug delivered to the lesion.
[0039] The system delivers a limited amount of ultrasonic energy non-invasively at a treatment position (e.g., cancer tissue) in a 3D space assisted by a robotic arm, and provides a feedback control loop of acoustic energy based on cavitation monitoring at the target area. The system makes patient medical treatment more effective by compensating tissue characteristics of changes in treatment position (e.g., depth) and movement of the treatment position caused by patient breathing or other movements during treatment. Depending on system configuration, clinical indications and treatment goals, ultrasonic energy may have high intensity, medium intensity, low intensity or a combination of intensities. The therapeutic agent may be a particle with a gas core, or a drug mixed with an ultrasound contrast agent to enhance ultrasonic cavitation and drug binding. The system utilizes images and a robotic arm to track the treatment position in real time and automatically moves a transducer module attached to the end of the robotic arm to deliver fine-tuned acoustic energy to the treatment position (e.g., a tumor). The present application greatly simplifies operation and processing procedures and reduces processing time and cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings required for use in the embodiments or the prior art description are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention, and for ordinary technicians in this field, other implementation schemes of the present invention can be obtained based on these drawings without creative work.
[0041] Figure 1A-1B Two exemplary systems of the present invention for targeted drug delivery and therapy enhancement are depicted. Different mounting orientations of the robotic arm relative to the clinician and the patient are illustrated. The ultrasound system includes real-time ultrasound imaging and a robotic arm to direct focused ultrasound energy to a target location in the abdominal region of a patient through drug delivery. Reference numeral 100 depicts a system for ultrasound enhanced drug delivery, reference numeral 101 depicts a patient, reference numeral 102 depicts a bed, reference numeral 103 depicts an ultrasound engine control system, reference numeral 104 depicts an ultrasound imaging display, reference numeral 105 depicts a display and location for therapy and cavitation monitoring, reference numeral 106 depicts a robotic arm, reference numeral 107 depicts a transducer module connected to the end of the robotic arm, and reference numeral 108 depicts a unit for drug delivery.
[0042] Figure 2The main functional block diagram and architecture of the present invention are depicted. Label 201 depicts a drug delivery control subsystem that provides a limited dose of therapeutic drugs and ultrasound contrast agents (microbubbles) to a patient, label 202 depicts an ultrasound treatment subsystem, label 203 depicts a cavitation treatment monitoring subsystem, label 204 depicts an ultrasound imaging target tracking subsystem, label 205 depicts a treatment volume transducer module spatial position control subsystem (also referred to herein as a "mechanical arm spatial position control subsystem"), label 206 depicts a 3D image registration and reconstruction module, label 207 depicts a dose plan calculation delivery timing control module, and label 108 depicts an exemplary drug delivery unit.
[0043] Figure 3 An exemplary diagram depicts the major functional and control blocks within the computing unit real-time controller 200 and their interconnection with the subsystems. The computing unit real-time controller 200 has the functionality to deliver a defined dose of drug and ultrasonic output energy to a target location within the patient's body, while monitoring the cavitation state and spatial location of the target and used as feedback to control the drug dose and ultrasonic output energy.
[0044] Figure 4 An exemplary configuration of controls and interconnections between the medication delivery control subsystem 201 and the medication delivery unit 108 is depicted.
[0045] Figure 5 An exemplary functional diagram is depicted of an ultrasound therapy subsystem 202 connected to a therapy transducer 219 to generate therapeutic ultrasound for medical treatment.
[0046] Figure 6 An exemplary functional diagram of the cavitation therapy monitoring subsystem 203 and its interconnection with the broadband receiving sensor 218 is depicted.
[0047] Figure 7A-7B Two exemplary configurations of the transducer module 107 are depicted, including a frame 230, an ultrasound imaging transducer 231, a therapy transducer 219, and one or more broadband receive sensors 218 for cavitation monitoring. Fig. 7A An exemplary transducer module 107 is depicted wherein an imaging transducer 231 and a separate therapy transducer 219 are located within a transducer frame 230 wherein a plurality (eg, 8) of broadband transducers 218 (eg, PVDF broadband transducers) surround the imaging transducer 231 for cavitation monitoring. FIG. Figure 7B Another exemplary transducer module 107 is depicted in which a single transducer array 220 is used for imaging, therapy, and cavitation detection. The multifunctional transducer may be a one-dimensional linear / phased array or a two-dimensional array.
[0048] Figure 8An exemplary configuration of displays for treatment, cavitation monitoring, and position is depicted. In the upper half of the display, it shows an ultrasound B-mode image of the tissue with the intended treatment positions overlaid to cover the area to be treated. During treatment, a cavitation detection map is also overlaid on the B-mode image. A measure of the cavitation dose is displayed on the upper right side of the display with a steady-state cavitation threshold and an inertial cavitation threshold. In the lower half of the display, the intended treatment position, determined automatically by the dose planning calculation or manually by the clinician, is overlaid on a 3D reconstructed volumetric image. Treatment progress is displayed in real time on the lower right.
[0049] Fig. 9 An exemplary configuration of a linear transformation from an expected target position [Ixi, Iyi] localized by ultrasound imaging and a current target position [1xj, Iyj] detected by cavitation monitoring to the robot base coordinates or global coordinates is depicted. DETAILED DESCRIPTION
[0050] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.
[0051] The terms used in this disclosure have their conventional meanings in the field to which they belong. Here are the definitions of several terms in this disclosure. If the conventional meaning of the term is inconsistent with the definition herein, the definition herein shall prevail.
[0052] The terms “1D”, “2D”, “3D”, “4D”, “5D”, “6D”, etc. mean one dimension, two dimensions, three dimensions, four dimensions, five dimensions, six dimensions, etc.
[0053] As used herein, the term "ultrasound contrast agent (UCA)" refers to a microbubble contrast agent used for ultrasound imaging, which is used to enhance ultrasound backscattering (reflection) of ultrasound waves, and produces an ultrasound image with increased contrast due to its high echo characteristics in the blood flow, which can improve the visual contrast of blood flow relative to surrounding tissues. These micron-sized particles include a gas core surrounded by a microbubble shell, which can be composed of albumin, galactose, lipids or polymers, and are injected into the circulatory system in the form of intravenous injection.
[0054] The term "B-mode imaging" means a two-dimensional ultrasound image consisting of bright dots representing ultrasound echoes. The brightness of each dot can be determined by the amplitude of the returning echo signal. This enables visualization and quantification of anatomical structures, as well as imaging of diagnostic and therapeutic procedures for small animal studies.
[0055] The terms "coupled", "connected" and "associated" generally mean electrical, electromagnetic and / or physical (eg, mechanical or chemical) coupling or linking, and do not exclude the presence of intermediate elements in the coupling or linking. The associated items lack specific contrary language.
[0056] The term "program" or "software" as used herein refers in a general sense to any type of computer code or computer executable instruction set that can be used to program a computer or other processor to implement various aspects. As described above, in addition, it should be understood that according to one aspect, one or more computer programs do not need to reside on a single computer or processor when executed to perform the methods of the present application, but can be distributed in a modular manner among multiple different computers or processors to implement various aspects of the present application.
[0057] The term "intended treatment location" is used to describe the location to be treated, which is manually selected by the clinician operator from the ultrasound image or automatically determined by calculation from the dose plan.
[0058] The term "current treatment position" is used to describe the location to which ultrasound energy is delivered. The location can be determined from the cavitation map to determine the current treatment position. The center of the cavitation area is defined as the current treatment position. At any moment in time, when cavitation occurs, the current treatment position is recorded. Ideally, the current treatment position overlaps with the intended treatment position, but may deviate from the intended treatment position due to changes in tissue motion, system control accuracy, and inhomogeneous properties of tissue. The current treatment position is detected by real-time imaging and used as control feedback for robot spatial position adjustment and therapeutic ultrasound energy delivery. The spatial motion of the intended treatment position is compensated by the ultrasound imaging and target tracking subsystems to update the current treatment position, as well as to compensate for other changes in system control and tissue properties.
[0059] The term "spatial position" is used to describe the position of the treatment module attached to the distal end of the robotic arm, which can be updated and optimized by the robotic arm spatial position control subsystem
[0060] It should also be noted that singular forms, such as the term "transducer" are intended to refer to a single transducer or a combination of transducers, and "fluid" is intended to refer to one or more fluids or mixtures. In addition, the words "proximal" and "distal" refer to the directions closer to and farther from the physician operating the device, respectively, with the transducer placed on top of the patient's body.
[0061] It should be understood that the embodiments of the present application described herein include "consisting of" and / or "consisting essentially of" embodiments.
[0062] References herein to "about" a value or parameter include (and describe) variations with respect to that value or parameter itself. For example, description referring to "about X" includes description of "X".
[0063] As used herein, reference to a "non" value or parameter generally indicates and describes "except" the value or parameter. For example, the method is not used to treat type X cancer, which means that the method is used to treat other types of cancer other than X.
[0064] As used herein, the term "about XY" has the same meaning as "about X to about Y."
[0065] As used herein and in the appended claims, the singular forms "a," "or," and "the" include plural referents unless the context clearly dictates otherwise.
[0066] The following detailed description is made with reference to the accompanying drawings. The drawings are not necessarily drawn to scale, explain the principles of the invention in the detailed description, and are not intended to provide the actual dimensions of the components in the system. This description will enable one of ordinary skill in the art to make and use the invention, and describes several embodiments, variations, substitutions and uses.
[0067] It should be understood that, unless otherwise stated, the present invention is not limited to use in humans. Although human patients are referenced herein, one of ordinary skill in the art will recognize that variations of the present invention are also applicable to other animals, such as mammals. Moreover, it should be understood that embodiments of the present invention can be applied to deliver ultrasonic energy to patients for therapeutic and / or diagnostic purposes. Drug delivery to enhance the treatment of pancreatic cancer is provided herein as an example of clinical application. One of ordinary skill in the art having the benefit of the present disclosure will understand that variations and embodiments of the present invention can be applied to different clinical applications and indications, including but not limited to neuromodulation, tissue ablation, cancer treatment, tissue excitation, tissue heating, tissue degeneration, drug activation, and immunotherapy. The disclosed devices and systems should not be construed as limiting in any way. On the contrary, the present disclosure is directed to all novel and non-obvious features and aspects of the various disclosed embodiments, individually and in various combinations and sub-combinations with each other. The devices and systems are not limited to any particular aspect or feature or combination thereof, nor do the disclosed embodiments require the presence of any one or more specific advantages or solutions to the problem.
[0068] Another aspect of the present application provides that the operations of some disclosed embodiments are described in a particular order for ease of presentation, and it should be understood that this description includes rearrangement unless a specific order is specifically required. The language is as follows, for example, in some cases, the operations described in sequence can be rearranged or performed simultaneously.
[0069] Further provided are only certain selected aspects of the system architecture, controller diagrams, clinical applications, and program / software-based implementations in this application. For example, it should be understood that the disclosed technology is not limited to any particular ultrasound imaging system or implemented computer language or program. In some embodiments, the present invention provides programs and software configured to perform the functions of any of the above-mentioned systems / subsystems.
[0070] This application describes various embodiments of systems and methods for delivering ultrasound energy via a robotic arm, optionally in combination with a therapeutic agent.
[0071] The present application provides a system 100 for using ultrasound to enhance medical treatment, which can perform 3D volumetric medical treatment, such as cancer treatment, wherein real-time cavitation state monitoring is used as feedback control of the delivery amount of ultrasound energy to the target to provide the patient with the same or similar amount of acoustic energy dose in the entire treatment area (e.g., tumor). The system 100 also uses an intelligent motion tracking method based on ultrasound imaging to monitor the treatment position in real time to provide real-time compensation for treatment dose and position changes caused by differences in patient tissue properties and organ motion.
[0072] The system provided in this article can eliminate the time required for the operator to locate the treatment position, and the mobile treatment module can be aimed at different locations in the patient's body to cover the entire volume to be treated to reduce the operator's treatment time and labor, thereby reducing treatment complexity and cost.
[0073] The system 100 described herein can adjust the acoustic energy intensity and dose customized for each patient's cavitation threshold due to differences in target depth, tissue properties, tissue motion, etc. Based on the shape of the tumor, the ultrasound engine control system automatically generates a customized treatment plan 103 .
[0074] The system 100 described herein ensures fully automated treatment using the motion of the robotic arm during the entire treatment process. The system 100 determines the treatment dose based on the desired treatment depth in the patient (see Figure 2 , Figure 3 ), a transducer module 107 included in the ultrasound probe is used to monitor the cavitation state while providing ultrasound energy treatment. The spatial position of the transducer module 107 is controlled by the mechanical arm 106 to accurately target the intended treatment position. The mechanical arm 106 follows the movement of the intended treatment position based on the tracking target position information of the ultrasound imaging captured by the imaging transducer in the transducer module 107 and processed by the ultrasound imaging target tracking subsystem 204, so that the treatment position is not affected by the motion displacement at the intended treatment position.
[0075] In some embodiments, the system 100 described herein is configured with one or more robotic arms (e.g., 106 in the figure) to meet the required degrees of freedom of motion, such as 1D, 2D, 3D, 4D, 5D, 6D or more degrees of freedom of motion. In some embodiments, one or more robotic arms are interconnected through a computing unit real-time controller (CURC) 200 to communicate spatial positions to other subsystems. In some embodiments, one or more robotic arms are used to track the motion of the same intended treatment position and adjust their spatial positions based on the motion tracking information.
[0076] In some embodiments, the ultrasound energy may have high intensity, medium intensity, low intensity, or a combination of these intensities, depending on the system configuration, clinical indication, and treatment goals. In some embodiments, the ultrasound energy is transmitted through an ultrasound probe that includes a transducer module 107 .
[0077] In some embodiments, the transducer module 107 includes a therapeutic transducer 219 that outputs ultrasonic energy for therapeutic purposes. In some embodiments, the transducer module 107 includes an imaging transducer 231 that outputs ultrasonic energy for imaging purposes. For example, the imaging transducer receives pulses for B-mode imaging, which can be used for current treatment position detection, tissue motion tracking, and cavitation detection. In some embodiments, the transducer module 107 includes one or more broadband receiving sensors 218 that obtain acoustic cavitation information and send it back to control the energy output of the system 100.
[0078] In some embodiments, the medical drug delivered in combination with ultrasound energy is a microparticle having a gas-like core or shell. In some embodiments, the medical drug is mixed with an ultrasound contrast agent to enhance ultrasound cavitation and drug action.
[0079] In some embodiments, the system 100 described herein is configured to deliver ultrasound energy in one or more treatment volumes within an individual using a transducer module. In some embodiments, the individual is an animal, including but not limited to animals such as monkeys, cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, most preferably a human.
[0080] In some embodiments, ultrasound imaging or signals may be used to track the position of the treatment volume and maintain the focus of the ultrasound energy field within the cross-section of the 3D treatment volume during a treatment cycle.
[0081] In some embodiments, the system 100 described herein is configured to monitor a treatment state at a particular treatment location or multiple treatment locations during ultrasound energy delivery, such as the onset of steady-state cavitation, the onset of inertial cavitation, or the onset of a boiling state. For example, in some embodiments, the system includes a cavitation treatment monitoring subsystem 203 that receives and processes cavitation signals detected by the transducer module 107.
[0082] In some embodiments, the system 100 described herein is configured to automatically calculate and adjust the system 100 settings to deliver a defined amount of ultrasound energy dose at a specific or multiple treatment locations based on the cavitation state detected by the cavitation therapy monitoring subsystem 203. For example, in some embodiments, the system 100 described herein is configured to automatically adjust the system 100 settings to increase or decrease the amount of ultrasound energy applied by the ultrasound therapy subsystem 202 via a specific or multiple treatment locations based on the values calculated by the dose plan calculation timing control module 207 until the onset of a certain steady-state cavitation or inertial cavitation is detected by the cavitation therapy monitoring subsystem 203. For example, in some embodiments, stable cavitation is detected by extracting steady-state cavitation from the harmonic signals of the RF signal received during the monitoring treatment. Inertial cavitation is detected by extracting broadband noise between harmonic signals from the RF signal received by the treatment monitoring subsystem 203. The presence of subharmonic signals and the presence of broadband noise in the received RF signal are defined as a stable cavitation threshold and an inertial cavitation threshold, respectively. The cavitation state detected at the treatment position is used to control the ultrasound dose or energy output relative to the defined steady-state cavitation threshold and inertial cavitation threshold. For example, if steady-state cavitation is required to enhance drug delivery while eliminating the possibility of any tissue damage due to thermal and inertial cavitation, the cavitation state is controlled between the defined steady-state and inertial cavitation threshold limits. If the cavitation state detected by the system is between the steady-state and inertial cavitation thresholds, the same dose should be used. In some embodiments, when the cavitation state detected at the target is below the defined threshold limit, more dose compensation will be calculated and planned by the dose plan calculation timing control module 207, and the increased amount of ultrasound energy will be delivered to the current treatment position of the treatment transducer 219 and controlled by the ultrasound treatment subsystem 202. In some embodiments, when the cavitation state detected at the current treatment position is above the defined threshold limit, a lower dose will be calculated and planned by the dose plan calculation timing control module 207, delivered by the treatment transducer 219 and controlled by the ultrasound treatment subsystem 202.
[0083] In some embodiments, the system 100 is configured to automatically adjust system settings to deliver a defined amount of ultrasound energy at a particular treatment location or locations, regardless of variations in treatment depth and individual treatment locations, such as tumor type and number.
[0084] In some embodiments, during ultrasound delivery, the computing unit real-time controller subsystem 200 within the system 100 described herein is configured to evaluate the results (e.g., cavitation intensity) from the cavitation therapy monitoring subsystem 203 in real time to provide input to the dose plan calculation timing control module 207 to process the calculation of the real-time microbubble and / or therapeutic drug dose and the adjustment of the ultrasound energy. Then, the ultrasound therapy subsystem 202 delivers the newly calculated ultrasound energy for a specific or multiple treatment locations, and the drug delivery control subsystem 201 delivers the newly calculated dose of microbubbles and / or therapeutic drugs. For example, see Figure 3 .
[0085] In some embodiments, the ultrasound imaging target tracking subsystem 204 is configured to automatically track the movement of the treatment position, for example, the movement of organs caused by the patient's breathing or body movement during treatment, and to capture real-time ultrasound images and ultrasound signals obtained from the transducer module 107 in real time. In some embodiments, automatic motion tracking is used to track a specific treatment position. In some embodiments, automatic motion tracking is used to track multiple treatment positions. For example, see Figure 3 .
[0086] In some embodiments, the manipulator spatial position control subsystem 205 is configured to automatically control the position and movement of the manipulator 106 in real time to compensate for the spatial motion (ΔXi, ΔYi, ΔZi) of the current treatment position. The tracking motion information of the predicted treatment position (Xi, Yi, Zi) is obtained from the ultrasound imaging target tracking subsystem 204 and calculated by the computing unit real-time controller subsystem 200. In some embodiments, the ultrasound imaging target tracking subsystem 204 provides the current treatment position information (Xj, Yj, Zj) as an input to the dose plan calculation timing control module 207. In some embodiments, the ultrasound image target tracking subsystem 204 obtained by ultrasound imaging and the corresponding spatial position (rx, ry, rz, Φx, Φy, Φz) of the transducer module 107 obtained from the manipulator spatial position control subsystem 205 are used together as inputs to the 3D image registration reconstruction module 206. rx, ry and rz are translation positions, and Φx, Φy, Φz are the rotation angle positions of the treatment module in the X-axis, Y-axis, and Z-axis manipulator coordinates, respectively. The robot coordinate center is defined at the center of the robot base and most of the time is mounted on a solid object. The imaging transducer 231, therapeutic transducer 219 and broadband transducer 218 within the transducer module 107 can be the same or separate two or three objects. For example, see Figure. The spatial transformation from transducer 231, 219 or 218 to the transducer acoustic module 107 is fixed and does not change once the transducer acoustic module 107 is manufactured and calibrated. For any position [Ix, Iy] detected by the imaging transducer 231, its spatial position in the robot coordinates can be determined by the following formula
[0087]
[0088] Wherein, R is the rotation matrix from the transducer module to the robot arm coordinates, which can be determined based on the rotation angles Φx, Φy, and Φz; Ta and Ra are the translation and rotation matrices from the imaging transducer 231 to the transducer module 107, respectively. Once the transducer module 107 is manufactured, Ta and Ra can be determined by calibration.
[0089] For example, the operator selects the desired treatment position (Ixi, Iyi) on the cross-sectional image of the patient's body detected by the imaging transducer 231. The spatial position of the desired treatment position in the robot arm coordinates can be determined by:
[0090]
[0091] Here,
[0092]
[0093] If the same imaging transducer 231 is used for cavitation or treatment monitoring, the detected current treatment position occurs at the cross-sectional image of the patient's body (Ixj, Iyj). The spatial position of the current treatment position in the robot arm coordinates can be determined as follows:
[0094]
[0095] The difference in spatial position is the change in distance from the current treatment position to the desired treatment position in X, Y, and Z coordinates. In some embodiments, the difference in spatial position (ΔXi, ΔYi, ΔZi) can be used for spatial motion compensation tracked and calculated by a tracking algorithm.
[0096] ΔP i =P(x j ,y j , z j )-P(x i ,y i , z i )=(Δx i , Δy i , Δz i )=(x j , x i ,y j -y i , z j -z i )
[0097] In some embodiments, the 3D image registration reconstruction module 206 processes the input signals to construct a 3D volume image, which is converted for dose plan calculation and delivered to the time series control module 207 to define the treatment plan in 3D space. For example, see Figure 3 .
[0098] In some embodiments, the computing unit real-time controller 200 is configured to integrate the target tracking output parameters, such as the desired treatment position (Xi, Yi, Zi) from the ultrasound imaging target tracking subsystem 204, the cavitation state monitored by the cavitation therapy monitoring subsystem 203, to provide real-time control of the ultrasound output energy of the ultrasound therapy subsystem 202, to maintain the ultrasound energy focus at the desired treatment position during the entire treatment period through the robotic arm spatial position control subsystem 205 (which controls the robotic arm 106), and to adjust the delivery time and dosage of the therapeutic drug and ultrasound contrast agent (e.g., microbubbles) through the drug delivery control subsystem 201 (which controls the drug delivery unit 108). For example, see Figure 3 .
[0099] In some embodiments, the transducer module 107 is used for 2D / 3D imaging scanning, ultrasound energy delivery, or a combination thereof to track specific intended treatment locations during treatment and guide ultrasound energy delivery to these locations. In some embodiments, ultrasound delivery is performed by a treatment transducer, such as a 2D / 1D array or a single element transducer. In some embodiments, the transducer module 107 also includes one or more broadband receiving sensors or broadband receiving sensor arrays for monitoring cavitation conditions.
[0100] In some embodiments, transducers for imaging and target tracking (e.g., 231), transducers for cavitation detection (e.g., 218), and transducers for ultrasonic energy delivery (e.g., 219) can be integrated into any combination of one, two, or three sensor modules. For example, depending on the clinical application and design configuration of the transducer modules, one transducer module can be used for imaging and therapy (e.g., including imaging transducer 231 and therapy transducer 219), while one or more separate transducers are used for cavitation monitoring (e.g., broadband receiving sensor 218). In some embodiments, the multifunctional transducer array 220 may have integrated 2D / 3D scanning, ultrasonic energy delivery, and cavitation monitoring functions (e.g., Figure 7BIn some embodiments, the system 100 described herein may include two robotic arms, a first robotic arm configured with a first transducer module including a therapeutic transducer, and a second robotic arm configured with a second transducer module, the second transducer module including an imaging transducer and one or more more broadband receiving sensors. In some embodiments, the system described herein may include three robotic arms, a first robotic arm configured with a first transducer module including a therapeutic transducer, a second robotic arm configured with a second transducer module including an imaging transducer, and a third robotic arm including a third transducer module of one or more broadband receiving sensors. In some embodiments, the ultrasonic engine control system 103 directs the transducer module 107 to send signals via a cable link or wirelessly.
[0101] In some embodiments, the center of the tumor region is set by the operator or clinician on the ultrasound imaging display 104 by clicking the mouse when the mouse pointer is located at the tumor center, or by touching the tumor center through a touch screen, or by pressing a button on the transducer module 107 to record the center position when the defined position is located at the tumor center shown on the ultrasound imaging display 104. This set position is the initial position of the treatment position.
[0102] In some embodiments, whenever a tumor area is visualized on the ultrasound imaging display 104, the operator / clinician clicks a button on the mechanical arm 106 or on the transducer module 107, and then the ultrasound imaging target tracking subsystem 204 acquires the ultrasound image (Ii), as well as the current transducer module (107) spatial position (rx, ry, rz, Φx, Φy, Φz), and the record of the position is sent to the 3D image registration reconstruction module 206 and saved for future treatment reference. In some embodiments, when the operator / clinician moves the transducer module 107 on the patient, even if the operator / clinician does not click the button on the mechanical arm 106, the ultrasound system 100 automatically records the trajectory of the mechanical arm 106 moving from one position to the next position.
[0103] In some embodiments, the 3D image registration reconstruction module 206 combines all 2D ultrasound images (Ii) acquired from the ultrasound imaging target tracking subsystem 204 and the corresponding transducer module (107) spatial positions (rx, ry, rz, Φx, Φy, Φz) acquired from the robotic arm spatial position control subsystem 205 to reconstruct the 3D treatment volume (e.g., Figure 3The dose plan calculation timing control module 207 calculates the dose (ultrasound energy and microbubble / drug dose) and delivery time sequence based on the expected treatment position (Xi, Yi, Zi) within the 3D volume reconstructed from all clinicians' selected B-modes. And the ultrasound energy is delivered to the current treatment position (Xj, Yj, Zj) registered from the transducer module position and the 3D reconstructed treatment volume. ΔXi, ΔYi and ΔZi are the expected treatment position displacements due to spatial motion compensation. In some embodiments, the range of motion distance relative to the intended treatment position that can be tracked and calculated by the tracking algorithm (any of ΔXi, ΔYi, ΔZi) is within any range of about 0 mm to about 20 mm, about 10 mm to about 20 mm, about 0 mm to about 10 mm, about 5 mm to about 10 mm, about 0 mm to about 5 mm, about 0 mm to about 2 mm, about 0 mm to about 1 mm, about 0.5 mm to about 1 mm, about 0 mm to about 0.5 mm, about 0 mm to about 0.1 mm, about 0.01 mm to about 0.1 mm, or about 0.001 mm to about 0.01 mm. In some embodiments, the range of motion distances (any of ΔXi, ΔYi, ΔZi) relative to the intended treatment position that can be tracked and calculated by the tracking algorithm is any of about 20 mm, about 19 mm, about 18 mm, about 17 mm, about 16 mm, about 15 mm, about 14 mm, about 13 mm, about 12 mm, about 11 mm, about 10 mm, about 9 mm, about 8 mm, about 7 mm, about 6 mm, about 5 mm, about 4 mm, about 3 mm, about 2 mm, about 1 mm, about 0.5 mm, about 0.1 mm, about 0.05 mm, about 0.01 mm, about 0.001 mm, or about 0 mm. In some embodiments, when there is no motion compensation, that is, the current treatment position overlaps the intended treatment position in all dimensions, then ΔXi=0, ΔYi=0, ΔZi=0. In some embodiments, the ultrasound system automatically moves the transducer module 107 to the origin of the intended treatment position, that is, the tumor center position selected by the clinician / operator.
[0104] In some embodiments, the dose plan calculation timing control module 207 optimizes the treatment positions and provides the most effective treatment plan by adding, subtracting or inserting treatment positions from the ultrasound image selected by the clinician. In some embodiments, the dose plan calculation timing control module 207 determines whether the treatment position is too close to other critical organs based on the 3D reconstructed volume image generated by the 3D image registration reconstruction module 206 and whether the number of treatment positions is sufficient to cover the entire cancer volume. In some embodiments, the dose plan calculation timing control module 207 recommends one or more new positions for adding treatment according to the size of the tumor.
[0105] In some embodiments, the spatial position of the transducer module 107 including the therapy transducer 219 is determined by the dose plan calculation and by the time sequence control module (e.g., Figure 3 The dose plan calculation timing control module 207 in the treatment plan is used for calculation and control. The mechanical arm 106 and the transducer module 107 move from one spatial position to another spatial position to confirm the scanning path after the treatment plan, and no ultrasonic treatment energy is turned on during the operation of the scanning path.
[0106] In some embodiments, the expected 3D treatment volume is segmented from a pre-recorded 3D CT or MRI image of the patient and used for dose plan optimization. The 3D reconstructed ultrasound treatment volume from the 3D image registration reconstruction module 206 is registered with the patient's 3D CT or MRI treatment volume using a 3D point cloud registration algorithm in the module 206. The dose is then calculated by the dose plan to determine the treatment area, and the dose plan calculation timing control module 207 is overlaid on the 3D reconstructed volume image registered with the pre-existing 3D CT or MRI image of the treatment area to verify and optimize the treatment position (see, e.g. Figure 8 ).
[0107] In some embodiments, the ultrasound therapy subsystem 202 initiates therapeutic energy delivery (e.g., output from the therapy transducer 219) while the cavitation state is detected via the transducer module 107 and monitored using the cavitation therapy monitoring subsystem 203. The dose of therapeutic ultrasound energy delivered is also quantified by the cavitation therapy monitoring subsystem 203 using a received broadband noise transmit signal from the broadband receive sensor 218 to detect inertial cavitation and a subharmonic transmit signal to monitor steady-state cavitation. The monitoring and quantification outputs are transmitted to the computing unit real-time controller subunit 200, and the cavitation state of the target is evaluated by the computing unit within the subsystem 200. Depending on whether the cavitation state is below steady-state cavitation (low), steady-state cavitation (yes), or above inertial cavitation (high; see Figure 3 The dose compensation signal is sent to the dose plan calculation timing control module 207, wherein the therapeutic ultrasound intensity is adjusted to increase, remain unchanged or decrease according to the cavitation state until the cavitation therapy monitoring subsystem 203 consistently detects steady-state cavitation.
[0108] In some embodiments, the system 100 described herein initiates treatment and automatically moves the transducer modules, at defined desired treatment locations, from one spatial location to another to deliver therapeutic ultrasound energy following a dose and treatment plan.
[0109] In some embodiments, the system 100 described herein captures post-treatment B-mode images at each treatment location for comparison with images obtained before treatment and as future reference.
[0110] In some embodiments, the system 100 described herein also includes an interface through which remote control of the non-invasive ultrasound system is provided by controlling the movement of the robotic arm 106, and the interface also provides for transmission of images and data.
[0111] In some embodiments, a cavitation dose metric (CDM) is calculated within the dose plan calculation timing control module 207 and is used to indicate the intensity of the cavitation effect, which is related to the effective ultrasound treatment dose. It monitors the safety and efficacy of treatment related to the degree of drug penetration for each patient, thereby monitoring the drug uptake by cancer cells. CDM combines steady-state cavitation metrics and inertial cavitation metrics, and calculates steady-state cavitation thresholds and inertial cavitation thresholds based on the power spectrum calculation of the RF signal monitored during treatment. The steady-state cavitation metric is calculated by integrating the amplitude of the RF signal spectrum over superharmonics and subharmonics within a specific bandwidth (e.g., 100kHz-600kHz) around the harmonics. The inertial cavitation metric is the integral of the root mean square (RMS) amplitude of the broadband emission detected by the broadband receiving sensor 218. The steady-state and inertial cavitation thresholds are reached when the steady-state and inertial cavitation metrics are higher than 3dB during treatment. Before treatment, the inertial cavitation threshold is higher than the steady-state cavitation. If the treatment is accompanied by microbubbles, the steady-state cavitation threshold (SCT) should be exceeded to enhance drug renewal. And the treatment should be set below the inertial cavitation threshold (ICT) to avoid tissue damage. If the treatment does not use microbubbles, it should be set above the inertial cavitation threshold to maintain the cavitation effect. The cavitation occurrence area is defined as the sum of all spatial location points on the B-mode image where the cavitation energy level is above the defined initial or steady-state cavitation threshold. When drug delivery utilizes the steady-state cavitation effect, if the CDM is lower than the SCT, the cavitation state is considered to be low and the ultrasound intensity should be increased until the CDM is greater than the SCT but less than the SCT plus 2dB. When inertial cavitation is used to induce moderate tissue damage, if the CDM reaches the ICT and remains within the ICT plus 2dB, the ultrasound intensity should remain unchanged. If the CDM exceeds the ICT by more than 2dB, the ultrasound intensity should be reduced through the control of dose planning calculation 207.
[0112] In some embodiments, the treatment plan and current treatment status may be displayed on the treatment monitoring display 105, which includes the cavitation image and intensity, the current treatment position and the expected treatment position determined by the dose plan calculation in the reconstructed 3D, the treatment volume, and the CDM status in the current treatment plane, etc. Figure 8 An exemplary display is given. Figure 8As shown, the intended treatment position within the region (i.e., the optimized treatment region determined by the dose plan calculation), the cavitation position in the cross section of the completed treatment region ("treatment region"), and the 3D treatment region are overlaid on the conventional treatment region ultrasound B-mode image. The cavitation intensity is monitored in real time and displayed on the upper right side of the display, showing the steady-state cavitation threshold and the initial cavitation threshold. The treatment monitoring display 105 also shows the optimized treatment region determined by the dose plan calculation overlaid within the 3D reconstructed volume image from the 3D image registration and reconstruction module 206. The treatment efficacy is monitored in real time by the cavitation dose measurement (CDM) and displayed on the lower right side of the treatment monitoring display 105. The cavitation position and intensity are displayed in real time within the intended treatment region, and the treatment region is superimposed on the B-mode image, providing clinicians with detailed information on the real-time treatment plan and treatment status, thereby greatly improving treatment safety. If the cavitation effect is detected to occur outside the intended treatment region, the treatment should be stopped and the position of the transducer module 107 should be readjusted. If treatment is found to be complete at one treatment location, the transducer module 107 should be moved to the next intended treatment location determined manually by the clinician or by the ultrasound engine control system 103 .
[0113] In some embodiments, the imaging from the treatment monitoring display 105 is a 1D plot over time to show the real-time cavitation status. In some embodiments, the imaging from the treatment monitoring display 105 is a 2D plot of the cavitation signal (e.g., color-coded cavitation intensity) superimposed on the B-mode image to show the location and intensity of cavitation occurrence.
[0114] Figure 1A-1B An exemplary system 100 for enhancing medical treatment using ultrasound is shown for applying ultrasound energy to a medical treatment via a robotic arm 106. It is configured to deliver limited ultrasound energy to a target treatment area, such as the upper and mid-abdominal regions of a patient's body. For example, the system can target a pancreatic cancer region and surrounding tissue to create cavitation within the patient's pancreas. The system can also be used to deliver focused ultrasound energy to other tissues or organs of the patient. The system can be configured to enhance treatment of different tissues or organs in combination with various treatment methods and / or ultrasound-mediated therapeutic agents, depending on the location and depth of the target tissue in the body.
[0115] As shown in Figures 1 and 2, Figure 1A-1BAs shown, the system 100 includes an ultrasound engine control system 103, an ultrasound imaging display 104, a treatment monitoring display 105 (hereinafter also referred to as a "treatment monitoring display"), a robotic arm 106, a transducer module 107, an ultrasound engine control system 103, and a drug delivery unit. The ultrasound engine control system 103 serves as a controller for the entire ultrasound system: it activates the treatment transducer 219, processes the cavitation signal detected by the transducer module 107, and modulates the transducer positioning mechanism through the robotic arm 106. The two user interfaces ultrasound imaging display 104 and treatment monitoring display 105 are configured to monitor, control, and synchronize ultrasound imaging, treatment treatment, drug delivery, and the movement of the robotic arm 106. The robotic arm 106 facilitates positioning the transducer module 107 on the patient's body 101. Figure 1A-1B Two exemplary system configurations are shown, with the robotic arm 106 having different mounting orientations relative to the clinician / operator and the patient 101. The robotic arm 106 can also be used to place other medical tools on the patient through the patient in addition to the transducer module 107. During treatment, the monitoring tool, such as a camera on top of the transducer module 107, is monitored.
[0116] like Figure 1A-1B As shown, a patient 101 is treated on a hospital bed 102. A clinician moves a transducer module 107 configured at the distal end of a robotic arm 106 to a treatment area, such as the patient's abdomen. An ultrasound imaging display 104 displays the patient's abdominal structure using an ultrasound B-mode image. The clinician / operator locates the intended treatment area in the patient's body by ultrasound imaging (e.g., the location of a tumor or the size of a lesion) displayed on a treatment monitoring display 105. An ultrasound engine control system 103 reconstructs a 3D volume image using B-mode images or received signals, and the spatial location of the captured image, and then develops a treatment plan for display on the treatment monitoring display 105. According to the treatment plan, the robotic arm 106 moves the transducer module 107 to aim at the first intended treatment location, and then applies treatment. The ultrasound energy generated from the transducer module 107 is adjusted until a cavitation effect is induced in the target area during treatment. The treatment monitoring display 105 displays the cavitation energy and position information in real time. By adjusting the ultrasound system control parameters based on the detection signals from the cavitation monitoring, the ultrasound energy delivered to the target is adjusted to the level defined in the treatment plan developed by the ultrasound engine control system 103, and the location of the ultrasound energy delivery is also adjusted to follow the movement of the treatment location due to the patient's breathing by using the robotic arm 106 and spatial position tracking based on ultrasound imaging. After each location is treated, the robotic arm 106 moves to the next treatment location according to the treatment plan until the defined treatment volume is fully covered.
[0117] Figure 2The main components of the ultrasound engine control system 103 are depicted, as well as its coordination with other components of the ultrasound system 100. In some embodiments, the ultrasound engine control system 103 includes a computing unit real-time controller 200, a drug delivery control subsystem 201, an ultrasound therapy subsystem 202, a cavitation therapy monitoring subsystem 203, an ultrasound imaging target tracking subsystem 204, and a robotic arm spatial position control subsystem 205.
[0118] The computing unit real-time controller 200 includes a central processing unit (CPU), a 3D image registration and reconstruction module 206, and a dose plan calculation and delivery timing control module 207. In some embodiments, the ultrasonic engine control system 103 also includes a power supply ( Figure 2 In some embodiments, the ultrasonic engine control system 103 also includes other standard system hardware and software, such as an operating system, multiple radio frequency (RF) amplifiers, a display driver, interconnect cables to the transducer module 107, a system display, and a keyboard.
[0119] The robot arm 106 is used for six-axis displacement control, which is modulated by the dose plan calculation time sequence control module 207, the treatment volume and the robot arm space position control subsystem 205. A real single-board computer time controller board, such as an FPGA board ( Figure 2 107 ), together with the software within the ultrasonic engine control system 103, to receive dose information, cavitation information and mechanical position information, and send to the computing unit real-time controller 200. The computing unit real-time controller 200 performs operations, monitors cavitation, calculates treatment dose, processes and adjusts ultrasonic energy parameters, and sends feedback to each subsystem of the module. The drug delivery control subsystem 201 sends signals to the drug delivery unit 108, and the ultrasonic treatment subsystem 202 and the cavitation treatment monitoring subsystem 203 coordinate and control the transducer module 107. The signals / information obtained by the transducer module 107 are sent to the ultrasonic imaging target tracking subsystem 204 for imaging display and target tracking purposes.
[0120] Figure 3 Depicted is an exemplary functional diagram of the ultrasound engine control system 103 and its coordination with other components of the system 100. The ultrasound engine control system 103 includes a computing unit real-time controller 200 interconnected with drug delivery, a control subsystem 201, an ultrasound therapy subsystem 202, a cavitation therapy monitoring subsystem 203, an ultrasound imaging target tracking subsystem 204, and a robotic arm spatial position control subsystem 205.
[0121] The computing unit real-time controller 200 includes a 3D image registration and reconstruction module 206 and a dose plan calculation timing control module 207. The ultrasonic engine control system 103 synchronizes the motion and function of the robot arm 106, the transducer module 107 and the drug delivery unit 108.
[0122] In this example, in one embodiment, the ultrasonic engine control system 103 includes not only the traditional functions of the ultrasonic imaging system, such as the imaging of the ultrasonic imaging target tracking subsystem 204 and some limited therapeutic power output by the ultrasonic treatment subsystem 202, but also several unique features for medical treatment, such as the drug delivery control subsystem 201 for drug delivery control, the cavitation treatment monitoring subsystem 203 for cavitation monitoring, the robotic arm spatial position control subsystem 205 for the motion control of the robotic arm 106, the 3D image registration and reconstruction module 206 for 3D image registration and reconstruction, the dose plan calculation timing control module 207 for dose planning and timing control, and other calculation and control functions, including the transducer module 107 of the imaging transducer 231 is configured with 6D motion capability at the distal end of the robotic arm 106, wherein the robotic arm 106 is controlled based on the signal processed and output from the computing unit real-time controller 200 and the software within the host system, and the robotic arm 106 moves the transducer module 107 toward or away from the patient's body and provides 3D spatial motion capability, covering the treatment volume. The intended treatment position in the region is detected by the imaging transducer 231 within the transducer module 107. The pulse echo signal acquired by the imaging transducer 231 is processed by the ultrasound imaging target tracking subsystem 204 into a B-mode ultrasound image to determine that the intended treatment position (Xi, Yi, Zi) selected manually by the clinician or the dose plan control 207 automatically corresponds to the current ultrasound B-mode image. The current treatment position (Xj Yj, Zj) is measured in the coordinates of the imaging transducer 231. The current treatment position may be displaced due to organ motion from the patient's breathing. At the same time, the acquired image (Ii) is sent to the 3D image registration reconstruction module 206 together with the corresponding spatial position (rx, ry, rz, Φx, Φy, Φz) of the transducer module 107 to reconstruct the initial image. 3D volume image, after the initial 3D reconstruction of the B-mode image, the 3D treatment volume is determined, and the spatial motion profile of the treatment position (e.g., tumor) can also be reconstructed within the 3D volume image. The intended treatment positions and their distances relative to each other are optimized by the dose plan calculation. The current treatment position together with the cavitation state is processed by the dose plan calculation timing control module 207 to generate a new delivery time sequence and motion compensation control, for example, for the ultrasound treatment subsystem 202 to adjust the ultrasound energy dose and delivery time, for the drug delivery control subsystem 201 to adjust the delivery time and dose of the drug / microbubble, and for the robotic arm spatial position control subsystem 205 to calculate the delivery time to perform changes and motion compensation ultrasound energy and drug / microbubble between the expected and current treatment positions. In this way, the controlled delivery of ultrasound energy and microbubbles / therapeutic drugs to all treatment positions in the patient's body can be met and monitored simultaneously. This treatment method provides great improvements in the safety and efficacy of drug delivery for cancer treatment.
[0123] In some embodiments, a real-time treatment position compensation program (such as a real-time treatment position compensation program established within the computing unit real-time controller subsystem 200) is provided, which calculates the spatial position (rxj, ryj, rzj) and the motion compensation (Φx, Φy, Φz) of the transducer module based on the corresponding treatment position (Xj, Yj, Zj) and the spatial motion (ΔXi, ΔYi, ΔZi) of the treatment position relative to the expected treatment position (Xi, Yi, Zi) using real-time ultrasound images (image of the current treatment position [Ixj, Iyj], relative to the image of the expected treatment position [Ixi, Iyi]) for mapping.
[0124] In some embodiments, the program may input a series of base values:
[0125] 1) Expected treatment location (Xi, Yi, Zi);
[0126] 2) the corresponding registered B-mode image (Ixi, Iyi) of the intended treatment position;
[0127] 3) The corresponding spatial positions of the transducer modules when capturing B-mode images (rxi, ryi, rzi, Φx, Φy, Φz).
[0128] For example, input base values are used for various spatial treatment positions so as to cover the entire expected treatment volume of the tumor. Within the cross section of the expected treatment volume, there may be several expected treatment positions. In some embodiments, the program automatically samples the expected treatment positions (Xi, Yi, Zi) during scanning of the expected treatment volume (e.g., a tumor) and aligns each expected treatment position (Xi, Yi, Zi) with the corresponding B-mode image (Ixi, Iyi) of the expected treatment position, and the corresponding spatial position [(rxi, ryi, rzi), Φx, Φy, Φz] of the transducer module when the B-mode image is captured. During treatment, the program compares the B-mode image of the real-time treatment position ([1xj, Iyj]) and the B-mode image of the expected treatment position (Ixi, Iyi), which reflects the real-time (current) treatment position (Xj, Yj, Zj), and then the spatial motion (ΔXi, ΔYi, ΔZi) of the treatment position relative to the expected treatment position (Xi, Yi, Zi) can be calculated by the program according to the formula: ΔXi=Xj-Xi, ΔYi=Yj-Yi, ΔZi=Zj-Zi.
[0129] In some embodiments, when there is no motion compensation / spatial motion of the treatment position, i.e., the current treatment position overlaps the intended treatment position in all dimensions, ΔXi=0, ΔYi=0, ΔZi=0. The spatial position of the transducer module will remain aimed at the intended treatment position until the treatment is compiled. The robotic arm 106 then moves the transducer to the next predetermined treatment position. Finally, the program calculates the real-time spatial position of the transducer module (i.e., the position to which the transducer module should move due to patient / organ motion) according to the following formula: ΔP=P(xj, yj, zj)-P(xi, yi, zi).
[0130] In some embodiments, a real-time treatment dose compensation program (e.g., a real-time treatment dose compensation program established in the computing unit real-time controller subsystem 200) is provided, which actually calculates ultrasound / therapeutic drug dose compensation based on the time of cavitation dose measurement (CDM). When the treatment utilizes steady-state cavitation, if CDM is less than SCT, the ultrasound intensity is increased until CDM is within the range of SCT to SCT+2dB. When CDM exceeds this range, the intensity is controlled by the dose compensation system 200 to decrease, otherwise the intensity remains unchanged. When the treatment utilizes inertial cavitation, if CDM is less than ICT, the intensity is increased to the range of ICT to ICT+2dB. When CDM exceeds the range, the intensity is reduced using a lower intensity setting. When the cavitation map is superimposed on the B-mode image, the real-time (current) treatment position (Xj, Yj, Zj) is displayed to deviate from the expected treatment position (Xi, Yi, Zi) to the B-mode imaging. The distance between the two positions (ΔXi, ΔYi, ΔZi) is adjusted to move the current position to the expected position through the subsystem 200. The adjustment is then transferred to the processing module position.
[0131] At the beginning of the treatment period, the therapeutic drug is delivered to the patient's intravenous cavity by the drug delivery unit 108. In some embodiments, the drug delivery unit 108 includes only a chemotherapy drug delivery unit 211. In some embodiments, the drug delivery unit 108 includes only an ultrasound contrast agent delivery unit 212. In some embodiments, the drug delivery unit 108 includes both, namely a chemotherapy drug delivery unit 211 and an ultrasound contrast agent delivery unit 212. The chemotherapy drug delivery unit 211 and / or the ultrasound contrast agent delivery unit 212 can be in the form of a syringe connected to an automatic infusion pump. The automatic infusion pump can be controlled individually or together with the drug delivery control subsystem 201. After the clinician identifies the intended treatment position from the ultrasound image displayed on the ultrasound imaging display 104, under the control of the ultrasound treatment subsystem 202, ultrasonic energy with a determined treatment dose is delivered to the intended treatment position. Among them, the dose is calculated by the dose plan timing control module 207 ( Figure 3) calculation and control. The cavitation therapy monitoring subsystem 203 will monitor the cavitation emission signals from the treatment position and process the received cavitation signals to determine the cavitation state. If steady-state cavitation is achieved and the cavitation intensity is within the cavitation threshold, for example, between the steady-state and inertial cavitation thresholds, the cavitation state signal is transmitted to the dose plan calculation timing control module 207, which further instructs the drug delivery control subsystem 201 to maintain the resistance dose. However, if cavitation does not occur or the cavitation is unstable, the cavitation state signal is sent to the dose plan calculation timing control module 207, which instructs the drug delivery control subsystem 201 to stop drug delivery or increase the amount of microbubbles. If the cavitation is too high, the cavitation state signal is sent to the dose plan calculation timing control module 207, which instructs the drug delivery control subsystem 201 to stop drug delivery or reduce the amount of microbubbles. During the above-mentioned drug delivery control process, the drug delivery control subsystem 201 is also synchronized with the ultrasound therapy subsystem 202 through the control of the dose plan calculation and the delivery time sequence control module 207. Based on the cavitation state of the signal from the cavitation and in the treatment monitoring subsystem 203, the ultrasonic energy delivered to the treatment site is adjusted to maintain the cavitation state required for the desired treatment effect, such as steady-state cavitation or inertial cavitation.
[0132] In some embodiments, the transducer module 107 (see, e.g., FIG. 7 ) includes one or more broadband receiving sensors 218 and a therapeutic transducer 219. In some embodiments, the ultrasound therapy subsystem 202 includes an ultrasound output energy control 213 and an optional signal amplifier 214 ( Figure 5 ). Therefore, in some embodiments, when high output acoustic power is required in clinical applications, the power amplifier 214 further amplifies the signal controlling the ultrasonic energy output before sending it to the treatment transducer 219. As the delivered ultrasonic energy is gradually increased, the cavitation therapy monitoring subsystem 203 monitors the onset of steady-state cavitation based on the signal sent from the broadband receiving sensor 218. In some embodiments, the cavitation therapy monitoring subsystem 203 includes a cavitation detection monitoring algorithm 215, an analog-to-digital (A / D) converter 216, and an optional preamplifier 217 (see Figure 6 ). Once a cavitation event occurs, the cavitation signal is detected by the broadband receiving sensor 218 within the transducer module 107 and optionally amplified by the preamplifier 217. The detected steady-state cavitation signal is converted by the A / D converter 216 and processed by the cavitation detection monitoring algorithm 215. The processed cavitation signal is sent to the computing unit real-time controller 200, which dynamically controls the drug delivery control subsystem 201 and the ultrasound treatment subsystem 202, thereby dynamically adjusting the ultrasound energy output. Maintain a steady-state cavitation state and optimize the drug dose to be delivered to the target during clinical treatment.
[0133] Figure 7A-7BTwo exemplary transducer modules 107 are depicted, including a frame 230 , an imaging transducer 231 , a therapy transducer 219 , and one or more broadband receive sensors 218 . Fig. 7A An exemplary configuration of the transducer module 107 is depicted, wherein an imaging transducer 231 and a separate therapy transducer 219 are located within the transducer module 107 , with a plurality of broadband receiving sensors 218 for cavitation monitoring surrounding the imaging transducer 231 . Figure 7B An exemplary configuration of the transducer module 107 is depicted, in which a single transducer array has integrated functions of imaging, therapy, and cavitation monitoring. The multifunctional transducer array (broadband receiving sensor 218, imaging transducer 231, therapy transducer 219) can be a stand-alone hardware, an off-the-shelf module, or a custom module. The multifunctional transducer array 220 is used for imaging, therapeutic ultrasound energy generation, and receiving cavitation signals, which simplifies the structure and implementation of the transducer module 107 in a clinical environment.
[0134] The biological effects in the target tissue caused by cavitation may include intense local heating, flow, pitting and cell rupture, depending on the intensity and duration of the ultrasonic energy delivered. In certain embodiments, when high-power and / or tightly focused ultrasonic energy is delivered to the target, the non-invasive ultrasonic system described herein can produce a local heat area around the target (e.g., tumor). In some embodiments, ultrasonic energy is delivered in combination with a thermosensitive therapeutic agent. In some embodiments, the thermosensitive therapeutic agent is not released until it is activated by ultrasonic energy. In some embodiments, the thermosensitive therapeutic agent is selected from lysolipid thermosensitive liposomes, polylactide, polyglycolide, ethylene vinyl acetate, poly (lactide-co-glycolide, poly (N-isopropylacrylamide), poloxamer and chitosan.
[0135] The system 100 described herein is compatible with a variety of therapeutic agents (and their pharmaceutical formulations). These agents are intended to provide multiple effects, such as antibiotic, antiviral, chemotherapeutic, cell repair and gene therapy activities, or a combination of antibiotic, antiviral, chemotherapeutic, cell repair and gene therapy activities. By way of example and not limitation, the classes of drugs that can be delivered include hydrophilic drugs, lipophilic drugs, liposomes, dendrimers, cyclodextrins, nanoparticles, microspheres, peptides, linear and globular proteins (e.g., up to 80 kDa), linear and globular gene therapy drugs of varying molecular weights, adeno-associated virus gene therapy drugs, and RNA / DNA.
[0136] In some embodiments, the systems described herein can deliver one or more chemotherapeutic agents, such as, but not limited to, atitracin, doxorubicin, aduxiliary, amsacrine, asparaginase, anthracycline, azacitidine, azathioprine, carmustine injection, bleomycin sulfate, busulfan, bleomycin, irinotecan hydrochloride, camptothecin, carboplatin, carmustine, erythromycin hydrochloride, chlorambucil, cisplatin, cladribine, actinomycin, cytarabine, cytosine, cytosine, cyclophosphamide, cyclophosphamide, actinomycin D, docetaxel, doxorubicin, daunorubicin, asparaginase, epirubicin, etoposide, fludarabine, fluorouracil, fudarabine, gemcitabine, topulacon, Hydroxyurea, daunorubicin, idarubicin, ifosfamide, ifosfamide, irinotecan, guanine tablets, levofloxacin, clalipin, toluidine, embicin, mercaptopurine, methotrexate, mitomycin, mitoxantrone, mithramycin, mitomycin, myleran, azasporin, vinorelbine, pentostatin, cytoreduction, vincristine, oxaliplatin, paclitaxel, berdine, pentostatin, cisplatin, plicamycin, procarbazine, mercaptopurine, leralrexed, taxotere, paclitaxel, teniposide, thioguanine, toudex, topotecan, valrubicin, vinblastine, vanbixifen, vinblastine, vindesine, vincristine, vinorelbine, VP-16 and Weimeng. In some embodiments, the therapeutic agent delivered by the system described herein participates in immunotherapy. For example, in some embodiments, the therapeutic agent is an antibody, such as an immune checkpoint inhibitor, including but not limited to anti-PD-1Ab, anti-PD-L1Ab, anti-PD-L2Ab, anti-CTLA-4Ab, anti-TIGITAb.
[0137] The system 100 described herein is compatible with various ultrasound contrast agents, such as gas-filled vesicles, gas-filled liposomes, and the like.
[0138] Ultrasound contrast agents can be configured to increase contrast in an ultrasound image of a subject. An increase in contrast means that the difference in image intensity between adjacent tissues visualized by ultrasound is enhanced. For example, the difference in image intensity can be enhanced by using one or more sets of imaging parameters. In some embodiments, the ultrasound contrast agent includes a gas vesicle (GV), such as a plurality of gas vesicles. In some embodiments, the gas vesicle is a genetically encoded gas vesicle. For example, the gas vesicle can be microbially derived, such as bacterially derived, a gas vesicle formed by a bacterium, such as a photosynthetic bacterium (e.g., a cyanobacterium), or the gas vesicle can be an archaebacterium-derived gas vesicle formed by an archaeon (e.g., a halophile).
[0139] In some embodiments, the gas sac is substantially spherical. In some cases, the gas sac is elliptical. Other shapes are possible, depending on the type of bacteria from which the gas sac is derived. For example, the gas sac can be cylindrical, or can have a cylindrical center portion with tapered ends, or can be rugby ball-shaped, etc.
[0140] In certain embodiments, the air vesicles have nanoscale dimensions, with precise dimensions and shapes that vary between genetic hosts. Nanoscale refers to an average size of the air vesicles of 1000 nm or less, such as 900 nm or less, including 800 nm or less, or 700 nm or less, or 600 nm or less, or 500 nm or less, or 400 nm or less, or 300 nm or less, or 250 nm or less, or 200 nm or less, or 150 nm or less, or 100 nm or less, or 75 nm or less, or 50 nm or less, or 25 nm or less, or 10 nm or less. For example, the average diameter of the air vesicles can be from 10 nm to 1000 nm, such as from 25 nm to 500 nm, including from 50 nm to 250 nm, or from 100 nm to 250 nm. "Average" refers to the arithmetic mean.
[0141] In some embodiments, the ultrasound contrast agent is a microbubble, such as FDA-approved microbubbles Optison, Definity, Lumanson. These microbubbles contain a gaseous core (e.g., perfluorocarbon) enclosed by a shell, and their size ranges between 1-4 μm, which is smaller than the size of red blood cells, allowing them to circulate freely within the vascular system.
[0142] In some embodiments, the vesicles / microvesicles are conjugated with targeting molecules (e.g., polypeptides, antibodies, or ligands / receptors) to provide a higher affinity of the vesicles / microvesicles to the target area (e.g., tumor). For example, in some embodiments, the vesicles / microvesicles are conjugated with antibodies that specifically recognize tumor antigens of the target tumor for treatment. In some embodiments, the vesicles / microvesicles are conjugated with targeting molecules (e.g., anti-VEGFR antibodies or VEGF polypeptides) that specifically recognize endothelial biomarkers (e.g., VEGFR) associated with tumor angiogenesis or inflammation.
[0143] After general medical diagnostic procedures, the patient is diagnosed with pancreatic cancer. The following clinical procedures apply before, during, and after treatment:
[0144] 1) The patient was evaluated and met the following patient selection criteria: a) The patient had undergone CT (computed tomography) or MRI (magnetic resonance imaging) to verify the stage, location, etc. of pancreatic cancer; b) The patient did not have cardiovascular disease or other diseases that would affect the duration of treatment (approximately one hour); c) The patient was evaluated with ultrasound imaging and pancreatic cancer was identified by imaging methods.
[0145] 2) After the patient lies on the treatment bed, the clinician / operator adjusts the system position to ensure that the robotic arm 106 is closest to the patient's bed and the transducer module 107 attached to the end of the robotic arm 106 can reach the treatment area patient.
[0146] 3) Adjusting the ultrasound imaging display 104 and the treatment monitoring display 105 for better visualization by the clinician while scanning the patient.
[0147] 4) Locking system wheels.
[0148] 5) Ultrasound gel is applied over the treatment area and the central tumor region is identified using the transducer module 107. The transducer module 107 is moved to different positions to scan different areas or aspects of the tumor. Whenever a tumor region is visualized, the clinician clicks a button on the robotic arm 106 to record the intended treatment location and save the image for future treatment planning.
[0149] 6) The system records the initial treatment position, which is the center of the tumor as determined by the clinician. The initial position is set as the origin of the treatment. As the clinician moves the transducer module 107, the system records the trajectory of the robotic arm (and therefore the distally connected transducer module) moving from one spatial position to the next at the click of a button by the clinician.
[0150] 7) The system combines all ultrasound images selected by the clinician and the corresponding spatial positions of the transducer module 107 attached to the distal end of the robotic arm 106 to reconstruct a 3D volume image using a 3D image registration and reconstruction module 206, wherein the image is recorded by the ultrasound imaging target tracking subsystem 204 and the corresponding spatial position of the transducer module is recorded by the robotic arm 106 spatial position control subsystem 205 when the image is captured. Once the 3D volume image registration and reconstruction module 206 is reconstructed within the 3D image, the tumor region will be identified and segmented in 3D space. Then, the expected treatment position corresponding to the above ultrasound image is processed by the dose plan calculation timing control module 207, wherein the expected treatment position is further optimized to provide the most effective treatment plan, i.e., by adding, reducing or inserting further treatment positions, such as determining whether the treatment positions are too close to each other or critical organs, and whether the number of treatment positions is sufficient to cover the cancer volume. The dose plan calculation timing control module 207 also recommends one or more new treatment positions based on the size of the tumor. Once the cancer treatment area and treatment plan corresponding to the 3D reconstructed volume image are optimized by the dose plan calculation timing control module 207, the dose plan calculation timing control module 207 will generate a set of delivery time sequences of ultrasound energy and send them to the ultrasound treatment subsystem 202 and a set of delivery time sequences of microbubbles and / or therapeutic drugs and send them to the drug delivery control subsystem 201. The dose plan calculation timing control module 207 will also move to a set of target treatment positions to cover the optimized treatment area, converting the conversion module into the spatial position of the transducer module. The target treatment position on the reconstructed image converted to the transducer module position (rxi, ryi, rzi, Φx, Φy, Φz) is compensated by tissue movement. The current treatment position is updated by the robotic arm spatial position control subsystem 205 to move the transducer module through the robotic arm 106.
[0151] 8) Before the actual treatment begins, the expected treatment position calculated and optimized by the dose plan calculation timing control module 207 is verified by moving the robotic arm 106 from one position to another based on the dose and treatment plan, which includes the delivery time sequence of ultrasound energy and microbubbles and / or therapeutic drugs, and the robotic arm 106 spatial position using the optimized treatment position calculated and generated from step 7) without turning on the treatment power. The operator will verify the optimized treatment position determined by the dose and treatment plan overlaid on the B-mode ultrasound image displayed on the ultrasound imaging display 104, and check whether there is any interference with the robot arm movement during the power-free treatment process.
[0152] 9) The operator can display the optimized treatment positions generated by the dose plan calculation on the treatment monitoring display 105 and deliver them to the time series control module 207 by overlaying them on the 3D reconstructed volume image generated by the 3D image registration and reconstruction module, while displaying the 3D CT or MRI image side by side on the 3D reconstructed volume image on the ultrasound imaging display 104, so as to verify and optimize the treatment position.
[0153] 10) The clinician verifies the treatment plan and the movement of the transducer module 107. If the treatment position is not satisfied, return to step 5) and repeat.
[0154] 11) Once the treatment plan and transducer module motion are approved, the system acquires a baseline B-mode image.
[0155] 12) Start intravenous injection of microbubble-drug conjugate according to the EU UCA administration procedure guidelines.
[0156] 13) The system automatically moves the transducer module 107 to the starting point of treatment, i.e. the center of cancer treatment.
[0157] 14) Turn on therapeutic energy delivery to detect microbubble cavitation while using the transducer module 107. Quantify inertial cavitation and subharmonic emission for steady-state cavitation by broadband noise emission, if the dose is insufficient, adjust the intensity until the system consistently detects steady-state cavitation.
[0158] 15) During treatment, the ultrasound system automatically moves the transducer module 107 including the therapeutic transducer 219 from one location to another using a robotic arm to deliver therapeutic ultrasound energy at a defined target area following the dose and treatment plan.
[0159] 16) The system automatically tracks patient motion using a tracking algorithm (described herein).
[0160] 17) Complete treatment.
[0161] 18) Post-treatment B-mode images were obtained from each treatment location and compared with images obtained before treatment for future reference.
[0162] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and inventive features disclosed herein.
Claims
1. A system for enhancing medical treatment using ultrasound, characterized in that include: An ultrasound imaging display capable of displaying an anatomical ultrasound image of a target; a treatment monitoring display capable of displaying in real time the anatomical ultrasound imaging of the target, the cavitation state of the target, and the position information of the target; A robotic arm capable of moving freely in space; a transducer module, the transducer module being configured at the end of the manipulator to move along the target, wherein the transducer module is capable of delivering therapeutic ultrasound energy to the location of the target, detecting the location of the target, obtaining ultrasound imaging information of the target, and monitoring the cavitation state of each of the targets; the manipulator follows the movement of the intended treatment location according to the tracking target location information of the ultrasound imaging captured by the imaging transducer in the transducer module and processed by the ultrasound imaging target tracking subsystem; The desired treatment position in the coordinates of the robotic arm ( I xi , I yi ) is determined in the following way: in, R i is the rotation matrix from the transducer module to the robot arm coordinates, according to the rotation angle Φ xi , Φ yi and Φ zi Sure; Φ xi , Φ yi and Φ zi are respectively the rotation angles of the transducer module about the X-axis, Y-axis, and Z-axis in the robot arm coordinates; T a and R a are the translation and rotation matrices from the imaging transducer to the transducer module, respectively; r xi , r yi and r zi is the translational position of the transducer module; a drug delivery unit capable of delivering a therapeutic agent and / or an ultrasound contrast agent to the target, wherein the drug delivery unit is delivered synchronously with the therapeutic ultrasound energy from the transducer module; and An ultrasonic engine control system comprises a computing unit real-time controller, wherein the computing unit real-time controller controls the movement of the robotic arm, controls the delivery of therapeutic ultrasonic energy from the transducer module, and processes the cavitation state received by the anatomical ultrasonic imaging from the transducer module and the spatial position of the transducer module, and is used for real-time display of anatomical ultrasonic imaging of the target, target position tracking motion compensation, cavitation monitoring, ultrasonic energy output control, and delivery of drug doses and delivery control of the drug delivery unit.
2. The system according to claim 1, characterized in that The transducer module includes separate transducer elements for each function, including a therapy transducer, an imaging transducer, and one or more broadband receive sensors.
3. The system according to claim 1, characterized in that The transducer module includes a single multifunctional transducer array integrated with the functionality of transmitting therapeutic ultrasound energy, detecting target location, and monitoring cavitation conditions from corresponding transducer elements.
4. The system according to claim 2 or 3, characterized in that: The transducer module also includes a frame surrounding the transducer element.
5. The system according to claim 1, characterized in that The transducer module is detachably mounted on the robotic arm.
6. The system according to claim 1, characterized in that The robotic arm has six degrees of freedom of movement.
7. The system according to claim 1, characterized in that The transducer module sends a signal to the ultrasonic engine control system via a cable line or wirelessly.
8. The system according to claim 2, characterized in that There are two robotic arms, one of which is equipped with the treatment transducer, and the other of which is equipped with the imaging transducer and one or more broadband receiving sensors.
9. The system according to claim 2, characterized in that There are three robotic arms, one of which is equipped with the treatment transducer, one of which is equipped with the imaging transducer, and another of which is equipped with one or more broadband receiving transducers.
10. The system according to claim 1, characterized in that Also included is an interface through which the movement of the robotic arm is controlled to achieve remote control of the system, and the interface is capable of providing image data to a remotely controlled location.
11. The system according to claim 1, characterized in that The anatomical ultrasound imaging is from a B-mode image or a 3D reconstructed image of multiple ultrasound images.
12. The system according to claim 1, characterized in that The imaging from the treatment monitoring display is a ID map showing the cavitation state over time, and / or a 2D map of the cavitation state overlaid on the anatomical ultrasound imaging.
13. The system according to claim 2, characterized in that The therapeutic transducer is capable of generating pulses for inducing steady-state or inertial cavitation with or without the ultrasound contrast agent.
14. The system according to claim 2, characterized in that The imaging transducer receives pulses for ultrasonic imaging of the anatomy.
15. The system according to claim 2, characterized in that The broadband receiving sensor receives pulses for cavitation monitoring or cavitation imaging.
16. The system according to any one of claims 1-3, 5-15, characterized in that: The ultrasonic engine control system also includes a robotic arm spatial position control subsystem under the control of a dose plan calculation timing control module to control the spatial movement of the robotic arm. The dose plan calculation delivery timing control module is included in the computing unit real-time controller.
17. The system according to claim 16, characterized in that The ultrasonic engine control system also includes an ultrasonic imaging target tracking subsystem, wherein the ultrasonic imaging target tracking subsystem receives the anatomical ultrasonic imaging from the transducer module at each target position and transmits it to the computing unit real-time controller.
18. The system according to claim 16, characterized in that The computing unit real-time controller includes a 3D image registration and reconstruction module and a dose plan calculation and delivery timing control module.
19. The system according to claim 18, characterized in that The 3D image registration and reconstruction module reconstructs a 3D volume image of the target using ultrasound imaging of each target position and the corresponding spatial position of the transducer module.
20. The system according to claim 19, characterized in that The dose plan calculation delivery timing control module processes the target position and 3D volume image of the target, and sends a motion compensation signal to the robotic arm spatial position control subsystem to perform motion compensation at each target position.
21. The system according to claim 19 or 20, characterized in that The ultrasonic engine control system also includes a cavitation therapy monitoring subsystem to provide real-time monitoring of the cavitation state as an input to the dose plan calculation delivery timing, and control the dose plan calculation delivery timing control module to generate a dose compensation plan and a delivery time sequence, wherein the cavitation therapy monitoring subsystem receives a cavitation state signal from the transducer module at each of the target positions.
22. The system according to claim 21, characterized in that The dose compensation plan delivery time series is generated by superimposing a cavitation state input of each of the target locations onto an ultrasound image of each of the target locations.
23. The system according to claim 21, characterized in that The ultrasonic engine control system also includes an ultrasonic therapy subsystem, wherein the ultrasonic therapy subsystem controls the transducer module to deliver therapeutic ultrasonic energy.
24. The system according to claim 21, characterized in that The ultrasonic engine control system includes a drug delivery control subsystem, wherein the drug delivery control subsystem controls the drug delivery unit to deliver the therapeutic agent and / or the ultrasonic contrast agent.
25. The system according to any one of claims 22 to 24, characterized in that: The dose compensation plan and delivery time sequence generated from the dose plan calculation delivery timing control module instructs the ultrasound therapy subsystem to adjust the dose and delivery time of the therapeutic ultrasound, and instructs the drug delivery control subsystem to adjust the dose and delivery time of the therapeutic agent and / or the ultrasound contrast agent.
